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Abstract 
GPR109B (HM74) is a putative G protein-coupled receptor (GPCR) whose cognate ligands 
have yet to be characterized. GPR109B shows a high degree of sequence similarity to 
GPR109A, another GPCR which was identified as a high-affinity nicotinic acid (niacin) 
receptor. However, the affinity of nicotinic acid to GPR109B is very low. In this study, we 
found that certain aromatic D-amino acids including D-phenylalanine, D-tryptophan, and 
the metabolite of the latter D-kynurenine, decreased the activity of adenylate cyclase in cells 
transfected with the GPR109B cDNA through activation of pertussis toxin (PTX)-sensitive G 
proteins. These D-amino acids also elicited a transient rise of intracellular Ca2+ level in cells 
expressing GPR109B in a PTX-sensitive manner. In contrast, these D-amino acids did not 
show any effects on cells expressing GPR109A. We found that the GPR109B mRNA is 
abundantly expressed in human neutrophils. D-phenylalanine and D-tryptophan induced a 
transient increase of intracellular Ca2+ level and a reduction of cAMP levels in human 
neutrophils. Furthermore, knockdown of GPR109B by RNA interference inhibited the 
D-amino acid-induced decrease of cellular cAMP levels in human neutrophils. These 
D-amino acids induced chemotactic activity of freshly prepared human neutrophils. We also 
found that D-phenylalanine and D-tryptophan induced chemotactic responses in Jurkat 
cells transfected with the GPR109B cDNA, but not in mock-transfected Jurkat cells. These 
results suggest that these aromatic D-amino acids elicit a chemotactic response in human 
neutrophils via activation of GPR109B. 
   
 
Irukayama-Tomobe et al. — Page 3 
Introduction 
GPR109B (also known as HM74) is an orphan G protein-coupled receptor (GPCR), which 
was cloned during a search for novel leukocyte chemoattractant receptors relating to 
receptors for IL-8, N-formyl peptide, and C5a (1). A related receptor, GPR109A (HM74A), 
has been identified as a receptor for nicotinic acid (niacin). GPR109A is highly expressed in 
adipose tissue and the spleen (2). Nicotinic acid inhibits adipocyte lipolysis by inhibiting 
hormone-sensitive triglyceride lipase (3). This anti-lipolytic effect of nicotinic acid involves 
the inhibition of cyclic adenosine monophosphate (cAMP) accumulation in adipocytes 
through Gi protein-mediated inhibition of adenylyl cyclase (4-6). Independently, Tunaru et al. 
reported that the mouse ortholog of GPR109A, named “protein upregulated in macrophages 
by interferon-γ” (mouse PUMA-G), is highly expressed in adipose tissue and is a nicotinic 
acid receptor (7). They reported that the nicotinic acid-mediated decrease in plasma levels of 
fatty acids and triglyceride was abrogated in mice lacking PUMA-G, indicating that 
PUMA-G mediates the anti-lipolytic and lipid-lowering effects of nicotinic acid in vivo. 
However, the mouse do not have an ortholog of GPR109B, which appears to be specific in 
primates. 
Although GPR109A and GPR109B are highly similar, displaying 96% sequence identity 
at the protein level (differing by only 15 amino acids), the two receptors are not simply 
polymorphic variants or splice variants. They are encoded by separate genes co-located with 
another orphan GPCR, GPR81, at chromosome 12q24.31 (8). Comparison of the cDNA 
sequences of GPR109A and GPR109B reveal 15 base changes as well as a 5-nucleotide 
insertion at the 3’ end, resulting in GPR109A possessing a shorter C-terminal tail. Although 
GPR109B was once reported to be a low-affinity receptor for nicotinic acid, the affinity of 
nicotinic acid to GPR109B is quite low at millimolar levels (2). Furthermore, an independent 
study reported that GPR109B does not appreciably bind nicotinic acid (7), suggesting the 
possibility that GPR109B is a receptor for another biologically active substance(s). The 
mRNA expression profiles of GPR109A and GPR109B partially overlap and are partially 
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distinct. GPR109A is detected in adipose tissue, lung, trachea, and spleen, while GPR109B 
is detected in adipose tissue, lung, spleen, and peripheral blood leukocytes (2). Here we have 
identified a novel mechanism by which some aromatic D-amino acids may regulate cellular 
responses through activation of GPR109B. We identified D-phenylalanine (D-Phe), 
D-tryptophan (D-Trp), and D-kynurenine (D-Kyn, a metabolite of D-Trp) as agonists for 




Cloning of Human GPR109B and GPR109A. Transcriptional open reading frames 
(ORF) of GPR109A or GPR109B were amplified by PCR from human genomic DNA as a 
template using the following primers: 5’-CCCTTAAGGCCACCATGAATCGGCACCATC-
TGCA and 3,’-CCGGAATTCCTCGATGCAACAGCCCAACTG for GPR109B; 5’-CCCTTA-
AGGCCACCATGAATCGGCACCATCTGCA and 3’-CCGGAATTCAGGAGAGGTTGGGCC-
CAGATA for GPR109A. The amplified products were tagged with GFP at their 3’ termini 
and subcloned into a mammalian expression vector (pIRESneo2, from Clontech, CA, USA). 
Both strands of the cloned DNA were sequenced with a DNA sequencer. 
 
Cell Culture and Transfection. Chinese hamster ovary (CHO)-K1 cells were cultured in 
DMEM/HamF12 supplemented with 10% FCS (Sigma-Aldrich), 100 IU/ml penicillin, and 
100 µg/ml streptomycin. Then, 4 µg DNA was mixed with 6 µl Fugene6 in 0.3 ml Opti-MEM 
(Invitrogen-Gibco, NY, USA) and incubated at room temperature for 30 min. The cells were 
exposed to the Fugene6/DNA mixture in 2 ml of 10% FCS DMEM/ HamF12. 
For the generation of stable cell lines for the CRE-luciferase assay, CRE-luc 
reporter(9) and pCDNA3.1/Zeo (Invitrogen-Gibco) were used to transfect CHO-K1 cells 
seeded in six-well dishes and grown to 50% confluence as described above. These cells were 
maintained in DMEM/ HamF12 containing 10% FCS. At 24 h post-transfection, the medium 
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was supplemented with 500 µg/ml Zeocin for selection of antibiotic-resistant clones. Several 
resistant clones were isolated by limiting dilution and examined for the expression of the 
reporter protein by stimulation with forskolin (Sigma-Aldrich). The clone that showed 
highest luciferase activity (CHO-CRE6) was used for the experiment. 
For the generation of stable cell lines for GPR109A and GPR109B, CHO-CRE6 
cells were again transfected with pIRESneo-GPR109A::GFP or pIRESneo-GPR109B::GFP. 
At 24 h after transfection, 500 µg/ml G418 was added to the medium for selection of 
neomycin-resistant cells. The expression levels of each receptor were validated by 
fluorescent microscopy. Three lines with high expression for each receptor were selected, 
maintained in DMEM/ HamF12 containing 10% FCS and 500 µg/ml Zeocin,G418, and used 
for further analysis. 
 For the generation of stable cell lines of Jurkat cells expressing GPR109B, the 
GPR109B gene was subcloned into the pEB vector (10). pEBGPR109B::GFP was used to 
transfect Jurkat cells by electroporation (voltage: 260 V). These cells (107 cells) were 
maintained in RPMI1640 (Invitrogen-Gibco) containing 10% FCS. At 24 h after transfection, 
the medium was supplemented with 1 mg/ml G418 for selection of antibiotic-resistant cells. 
 
CRE::Luciferase Activity. Cells were seeded in a 96-well-plate and grown to confluence. Cells 
were treated with 0.3 µΜ forskolin and the indicated compounds. At 6 h later, luciferase 
activity was determined as described previously (9). 
 
Measurement of Intracelluar Calcium Concentration. Cells were loaded with 10 µM 
Fura-2AM (DOJINDO, Japan) in Hepes-Tyrode’s buffer at room temperature for 2 h. The 
cells were washed twice and resuspended in Hepes-Tyrode’s buffer at a density of 106 
cells/ml and seeded in a 96-well plate. Intracellular Ca2+ concentration was measured from 
the ratio of emission fluorescence of 500 nm by excitation at 340 or 380 nm using a 
Functional Drug Screening System (FDSS) 3000 (Hamamatsuphotonics, Japan). 
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Measurement of cAMP. The cells were seeded on 96-well plates (2x104 cells per well) and 
cultured for another 24 h. The medium was replaced with 75 µl serum-free DMEM 
containing 1 mM IBMX, and incubated at 37˚C for 20 min. The reaction was initiated by 
adding 25 µl of ligand solution containing designated ligands and forskolin (final 10 or 50 
µM). After 15 min of incubation, cAMP level was assayed by an Homogeneous Time Resolved 
Fluorescence (HTRF) cAMP femtomolar assay system (Schering, USA).  
 
Chemotaxis Assay. Chemotaxis was measured using an EZ-TAXIScanTM (Effector Cell 
Institute, Tokyo, Japan). The granulocyte fraction prepared from human whole blood was 
used as neutrophils(11). Human neutrophils or GPR109B-Jurkat cells were examined for 
their chemotactic responses to D-amino acids as described previously (12). The neutrophils 
were suspended at 106 cells/ml in RPMI1640 medium supplemented with 20 mM HEPES 
and 0.1% bovine serum albumin. Medium containing 10-1 M D-phenylalanine, 10-2 M 
D-tryptophan, 10-6 M stromal cell-derived factor-1α (SDF-1α) or none (distilled water) was 
injected into the opposite compartment after injection of the cells. The concentration 
gradient between the start and end points reached a maximum at around 5-15 min and the 
maximum concentration difference per 10 µm (almost 1:100). To observe and record the 
migration of cells in the channel, a charge coupled device (CCD) camera or CCD video 
camera connected to a monitor display was used. The migration of cells in the channel was 
recorded for 60-240 min. 
 
RNA Interference. RNA interference was performed with DeliverX transfection reagents 
(Panomics), following the manufacturer’s instructions (13). Each pair of 21-nt 
oligonucleotides was synthesized and annealed.  Neutrophils were transfected with one of 
three different targeting regions of GPR109B. The target sequences used for GPR109B were 
5’-CCGUUCGUGAUGGACUACU -3’ 5’-CAUCACUGUUGGCCUAACA-3’, and 5’-GCAUCU-
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CUGGAGAAACAGU-3’. (target position: 241-259, 459-477, 1126-1144), At 18 to 20 h after 
transfection of human neutrophils with the siRNA, cAMP levels following ligand 
administration were determined. To measure GPR109B RNA level, total RNA from the 
transfected neutrophils was extracted using an RNeasy kit (Invitrogen), and subjected to 
quantitative real-time RT-PCR analysis using primers for GPR109B or human GAPDH 
(TaqMan Gene expression assays, Applied Biosystems, CA, U.S.A.). Quantitative PCR was 
carried out using the ABI TaqMan Universal Master Mix kit with an ABI Prism 7900HT 
sequence detection system (Applied Biosystems). 
 
Data Analysis. Data were expressed as mean ± S.E.M. One-way analysis of variance 
(ANOVA) followed by Bonferroni test was used for statistical comparison among the various 




In the frame of a general strategy for characterizing ligands for orphan GPCRs, we 
established CHO-K1 cell lines co-expressing orphan receptor cDNAs and a luciferase 
reporter driven by a cAMP response element (CRE). We screened a library of ~600 natural 
bioactive compounds and their derivatives including lipids, amino acids, and others. During 
this procedure, we found that certain D-amino acids, namely D-Phe, D-Trp, and D-Kyn, 
inhibited the CRE::luciferase activity (up to ~80%) induced by forskolin in CHO-K1 cells 
stably expressing GPR109B (CHO-GPR109B cells) in dose-dependent manner (Fig. 1). The 
EC50 values of the responses to these ligands were 9.02 µM, 3.72 µM, and 2.61 µM, 
respectively (Fig. 1). The inhibitory effects of these D-amino acids on luciferase activity was 
confirmed in three independent lines of stable clones expressing GPR109B (data not shown). 
Despite the high degree of sequence similarity between GPR109A and GPR109B, D-Phe, 
D-Trp, and D-Kyn showed no effect on the CRE::luciferase activity induced by forskolin in 
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CHO-GPR109A cells (data not shown). Other amino acids including L-Phe, L-Trp, L-Kyn, 
and their related compounds (Table 1) showed no effect on luciferase activity induced by 
forskolin in CHO-GPR109B cells (data not shown). In cells stably expressing another orphan 
GPCR, GPR81, which shows high similarity to GPR109B (52% amino acid identity), 
D-amino acids including D-Phe, D-Trp, and D-Kyn, did not inhibit the CRE::luciferase 
activity induced by forskolin (data not shown). 
 The results from these CRE::luciferase assays suggested that GPR109B couples to 
the Gi class of G proteins. In fact, the forskolin-stimulated production of cAMP was also 
inhibited by these D-amino acids in CHO-GPR109B cells (Fig. 2A). This inhibition was 
abolished by pretreatment of the cells with pertussis toxin (PTX) (Fig. 2B). In contrast, 
D-Phe, D-Trp, and D-Kyn showed no effect on forskolin-stimulated cAMP accumulation in 
CHO-GPR109A cells, whereas nicotinic acid significantly lowered cAMP levels as expected 
(2) (Fig. 2C). We also examined the effect of D-amino acids including D-Phe, D-Trp, and 
D-Kyn on intracellular calcium ion mobilization in CHO-GPR109B cells. These amino acids 
elicited a transient rise of intracellular Ca2+ levels in CHO-GPR109B cells in a dose 
dependent manner (Fig. 3). This response was also abolished by PTX pretreatment, 
suggesting that this calcium response is mediated via activation of PTX-sensitive G proteins 
in CHO cells (Fig. 3). These observations suggested that GPR109B predominantly couples to 
the Gi/o class of G-proteins. These amino acids elicited a transient rise of intracellular Ca2+ 
levels also in COS7 cells transiently transfected with GPR109B (data not shown). D-Phe, 
D-Trp, and D-Kyn, did not induce a rise of intracellular Ca2+ levels in CHO cells stably 
expressing GPR81 or GPR109A (data not shown). 
GPR109B mRNA has been reported in adipose tissue, lung, spleen, and peripheral 
blood leukocytes in humans (2, 14). We also found that the GPR109B mRNA was abundantly 
expressed in human neutrophils. By quantitative real-time RT-PCR analysis, we found that 
the expression of GPR109B mRNA was 4.8-fold higher in neutrophils than in monocyte 
fractions (Fig. 4A). Given the identification of GPR109B as a receptor for specific aromatic 
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D-amino acids, we investigated the effects of these D-amino acids on freshly prepared 
human neutrophils. Although we found that GPR109B couples to the Gi/o class of G proteins 
in transfected CHO cells, it is well established that many GPCRs couple to phospholipase C 
through the promiscuous G15/16 proteins in blood cells. Therefore, we first examined the 
effect of these D-amino acids on intracellular Ca2+ mobilization in neutrophils. D-Trp 
significantly elicited a transient rise of intracellular Ca2+ levels in human neutrophils (Fig. 
4B), but did not induce degranulation in contrast to some other chemotaxic factors such as 
fMLP (data not shown). We also found that D-Trp (1 mM) augmented the intracellular Ca2+ 
mobilization induced by fMLP (0.1 nM) (Fig. 4B), suggesting that D-Trp and fMLP can act 
synergistically on neutrophils. In contrast, L-Phe, L-Trp, or L-Kyn did not elicit a transient 
rise of intracellular Ca2+ levels in human neutrophils (data not shown). We also measured 
intracellular cAMP levels after stimulation of human neutrophils with these D-amino acids, 
and found that D-Phe, D-Trp, and D-Kyn decreased the forskolin-stimulated production of 
cAMP with similar potencies (Fig. 4C). 
 To examine whether these effects are mediated by GPR109B expressed in human 
neurtrophils, we performed an RNA interference experiment by transfecting human 
neutrophils with short interfering RNA (siRNA) sequences targeting the GPR109B mRNA. 
Quantitative real-time RT-PCR analysis of GPR109B mRNA levels in neutrophils after 
transfection with the GPR109B siRNA demonstrated a marked reduction of GPR109B 
mRNA levels to 49.5+2.0% compared with controls (neutrophils treated with mixture of 
unrelated siRNA sequences). Although the inhibitory response to D-Trp of cAMP production 
induced by forskolin remained intact in neutrophils transfected with scrambled siRNA, 
transfection with GPR109B siRNA significantly inhibited the decrease of cAMP levels by 
D-Phe and D-Trp (Fig. 4D). These observations confirmed that the effect of D-Trp on 
neutrophils is mediated by GPR109B. 
The observation that GPR109B seems to share similar signaling pathway with some 
chemotactic factors led us to test for chemoattractant activity of D-amino acids in 
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neutrophils using an optical assay device (the EZ-TAXIScan system). D-Phe at an end-point 
concentration of 100 mM induced marked chemotactic activity in human neutrophils. D-Trp 
at 10 mM at the end-point also induced significant chemotactic activity (Fig. 5A) (we could 
not investigate the chemotactic activity of D-Trp at 100 mM, because D-Trp is not soluble in 
water at 100 mM). It is worth noting here that, under our experimental conditions, the ratio 
of the attractant concentrations at the end-point (where the attractants are applied) and the 
start point (where the cells initially reside) is approximately 100:1. Therefore, under the 
conditions depicted in Fig. 5A, cells were exposed to ~1mM of D-Phe and 0.1 mM of D-Trp 
(see Materials and Methods). 
The fact that the chemotaxis assay requires very fresh preparations of neutrophils 
rendered siRNA transfection experiments highly difficult. Therefore, to examine whether 
the chemotactic responses of neutrophils to D-Phe and D-Trp are mediated by GPR109B in 
heterologous cells, we transfected the GPR109B cDNA into Jurkat cells, which do not 
detectably express endogenous GPR109B. D-Phe and D-Trp induced significant chemotactic 
responses in Jurkat cells expressing GPR109B, whereas these D-amino acids exerted no 
effects on Jurkat cells transfected with the empty vector (Fig. 5B). These results suggest 




Our present study suggests that GPR109B is a functional receptor responsible for 
the action of D-Phe and D-Trp on neutrophils. The identification of a signal-transducing 
receptor for D-amino acids in neutrophils opens a new perspective in the modulatory 
mechanism of immune system functions in various pathophysiological situations. 
Recently, Jilek et al. reported that D-amino acids are present in some peptides from 
amphibian skin, and these residues are derived from the corresponding L-amino acids 
present in the respective precursors (15). They isolated an enzyme from frog skin that 
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catalyzes the isomerization of an L-lle in position 2 of a model peptide to D-allo-lle. They also 
reported that polypeptides related to the frog skin enzyme are present in several vertebrate 
species, including humans (15). Their findings raise the intriguing possibility that peptides 
containing a D-amino acid(s) are also present in humans. The presence of D-isomers may 
have been overlooked in hormonal, antibacterial or modulatory peptides of the immune 
system, or neuropeptides that have been characterized earlier. Neutrophils play a key role in 
the early steps of inflammatory processes. D-amino acids, as peptide metabolites, could 
induce activation of the immune system, leading to inflammatory responses. The 
development of therapeutic strategies to block neutrophil recruitment and activation might 
be beneficial in a number of diseases characterized by an inflammatory component. 
Therefore, the identification of GPR109B as a signaling receptor for D-Phe and D-Trp could 
potentially lead to new therapeutic strategies. 
 hGPCR48 (TG1019), which has high sequence similarity to GPR109B (41% amino 
acid identity), was revealed to be a receptor for 5-oxo-ETE (16). This eicosanoid is also 
known to be a potent chemotactic factor for eosinophils and neutrophils (17, 18). In addition 
to several GPCRs for leukocyte chemoattractants, (such as IL-8, C5a, fMLP, PAF, and LTB4), 
human GPR43, which displayed dual coupling through the Gi/o and pertussis 
toxin-insensitive Gq protein families, was uncovered as a neutrophil-specific receptor for 
short chain fatty acids (SCFAs) (19). SCFAs, such as sodium acetate and sodium propionate, 
are produced as metabolic byproducts of anaerobic bacteria, and induce neutrophil 
chemotaxis at an optimal concentration of 1 mM (19). Since some D-amino acids are also 
contained in bacterial components, such as D-Phe in peptidoglycans, they might also act as 
bacterially-derived chemoattractants through GPR109B. 
 We and others have not been able to identify ESTs or genomic fragments encoding a 
GPR109B ortholog in mammalian species other than humans and chimpanzees. This 
suggests that GPR109B may be the result of a very recent gene duplication event, and 
GPR109A and GPR109B might serve as a model to study the evolution of the GPCR gene 
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family. Considering that GPR109B might play a role in the defensive mechanism by 
leukocytes, distinct environmental conditions and evolutionary niches for different species 
could lead to different selective pressures to the GPR109 family of genes. 
Both GPR109A and GPR109B are expressed in adipose tissue. Nicotinic acid (niacin), 
via GPR109A, is reported to exert lipid-lowering effects by decreasing the fatty acid output 
from adipose tissue. These observations suggest the intriguing possibility that D-Phe and 
D-Trp may also have a lipid-lowering effect in humans. Since niacin has well-documented 
adverse effects such as severe persistent hypotension and cutaneous flushing, a 
GPR109B-selective agonist might potentially be a better therapeutic agent. 
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Figure Legends 
 
Fig. 1. Identification of D-amino acids as agonists for GPR109B. CHO-K1 cell 
lines expressing GPR109B along with the CRE::luciferase reporter plasmid were incubated 
with various concentrations of designated D-amino acids, together with 0.3 µM forskolin. All 
values are expressed as a percentage of the activity induced by 0.3 µM forskolin only. Data 
are mean ± S.E.M. of three independent experiments, each performed in triplicate. D-Phe, 
D-phenylalanine; D-Trp, D-tryptophan, D-Kyn, D-kinurenine; NA, nicotinic acid (niacin). 
 
Fig. 2. D-amino acids act on GPR109B and activate pertussis toxin-sensitive 
classes of G-proteins in CHO cells. A, D-amino acids inhibit cAMP accumulation 
through GPR109B via activation of PTX-sensitive G proteins. CHO-K1 cell line expressing 
GPR109B was incubated with various concentrations of D-amino acids, D-Phe, D-Trp, and 
D-Kyn together with 10 µM forskolin. Content of cAMP is expressed as a percentage of 
control (value in absence of D-amino acids). Data are mean ± S.E.M. of three independent 
experiments, each performed in triplicate. B, CHO-K1 cell line expressing GPR109B was 
incubated with D-amino acids (1 mM) together with forskolin (10 µM) after incubation with 
100 ng/ml PTX or vehicle for 24 h. Content of cAMP is expressed as a percentage of control 
(value in absence of D-amino acids). Data are mean ± S.E.M. of three independent 
experiments, each performed in triplicate. C, D-Phe, D-Trp, and D-Kyn do not act on 
GPR109A. D-Phe, D-Trp and D-Kyn did not decrease level of intracellular cAMP in CHO 
cells expressing GPR109A, while nicotinic acid (NA) potently inhibited it. Data are mean ± 
S.E.M. of three independent experiments, each performed in triplicate. 
 
Fig. 3. Effects of D-amino acids on cytoplasmic Ca2+ concentration. Increase in 
intracellular calcium concentration after exposure to various amino acids in CHO-K1 cell 
line expressing GPR109B and effects of PTX treatment on D-amino acid-induced increases 
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in intracellular calcium concentration in CHO-GPR109B cells are shown. Data are 
expressed as percentage of the peak response induced by Uridine 5,-Triphosphate (UTP) 
(100 µM). *P < 0.05 vs. PTX (-). 
 
Fig. 4. Expression of GPR109B in human neutrophils (A). Expression of GPR109B 
mRNA in human neutrophils is determined by real-time RT-PCR analysis, and the relative 
expression level is expressed as percentage of that in human monocytes. Data represent 
mean value ± S.E.M. (n=4). *P < 0.05 vs. monocytes. 
 
D-Trp enhanced intracellular calcium mobilization induced by fMLP at a low 
dose in human neutrophils (B). Neutrophils were loaded with 10 µM Fura-2AM for 2 h 
at RT, and intracellular calcium mobilization was measured. All values are expressed as a 
percentage of control (fMLP, 100 nM). Data represent mean value ± S.E.M. (n=4). *P < 0.05 
vs. fMLP (0.1 nM) or D-Trp (1 mM). 
 
D-Phe, D-Trp and D-Kyn inhibit cAMP production in neutrophils through 
GPR109B (C). Neutrophils were incubated with D-amino acids together with 50 µM 
forskolin. After 15 min, cAMP accumulation was measured. cAMP content is expressed as a 
percentage of control in the absence of D-amino acids. Data are mean ± S.E.M. of three 
independent experiments, each performed in triplicate. (D) Effects of GPR109B 
knockdown on D-amino acids-induced decrease in cAMP level in human 
neutrophils. Transfection with GPR109B siRNA significantly inhibited the decrease of 
cAMP level by D-Phe and D-Trp in neutrophils as compared with control siRNA. 
 
Fig. 5. D-amino acids elicit chemotactic activity through activation of GPR109B. 
A, D-amino acids induced chemotaxis in human neutrophils. Chemotactic activities to D-Phe, 
D-Trp, or control (distilled water) recorded for 60 min were shown. All values are expressed 
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as a percentage of control. Data are the mean of two independent preparations of cells. B, 
D-amino acids induced chemotaxis in Jurkat cells expressing GPR109B. Chemotactic 
activities of Jurkat cells expressing GPR109B to D-Phe, D-Trp, SDF-α or control (distilled 
water) recorded for 240 min were shown. All values are expressed as a percentage of control. 






Supplementary table 1 Compounds tested for activation of GPR109B-CHO cells
Compound Name concentration (mM) response
0.1 N.D.
D-ASPARTIC ACID 0.1 N.D.
















D-PHENYLALANINE 0.1 cAMP ↓
D-PROLINE 0.1 N.D.
D-PYROGLUTAMIC ACID 0.1 N.D.




L-CYSTEINE SULFINIC ACID 0.1 N.D.
L-HOMOCYSTEINESULFINIC ACID 0.1 N.D.
2,4-DIHYDROXYPHENYLACETYL-L-ASPARAGINE 0.1 N.D.
HYPOTAURINE 0.1 N.D.
IMIDAZOLE-4-ACETIC ACID HCl 0.1 N.D.
O-PHOSPHO-L-SERINE 0.1 N.D.
SPAGLUMIC ACID 0.1 N.D.
S-SULFO-L-CYSTEINE SODIUM 0.1 N.D.
TAURINE 0.1 N.D.
L-KYNURENINE SULFATE 0.1 N.D.
D-KYNURENINE 0.1 cAMP ↓
KYNURAMINE 0.1 N.D.
N-ACETYLTRYPTAMINE 0.1 N.D.
AGMATINE SULFATE 0.1 N.D.
BUTYL-beta-CARBOLINE-3-CARBOXYLATE 0.1 N.D.





3,4-DIHYDROXYPHENYLACETIC ACID 0.1 N.D.
DL-4-HYDROXY-3-METHOXY-MANDELIC ACID 0.1 N.D.
4-HYDROXY-3-METHOXY-PHENYLACETIC ACID 0.1 N.D.
3-METHOXY-L-TYROSINE 0.1 N.D.








HARMANE HCl 0.1 N.D.
HARMALINE HCl 0.1 N.D.
HARMANE-1,2,3,4-TETRAHYDRO-3-CARBOXYLIC ACID 0.1 N.D.
HARMINE HCl 0.1 N.D.
TRYPTAMINE HCl 0.1 N.D.
trans-4-HYDROXYCROTONIC ACID 0.1 N.D.
OUABAIN 0.1 N.D.
6-FORMYLINDOLO [3,2-b] CARBAZOLE 0.1 N.D.
INDIGO 0.1 N.D.
INDIRUBIN 0.1 N.D.
4-HYDROXYPHENETHYLAMINE HCl 0.1 N.D.











(R,S)-3-(2-PIPERIDINYL) PYRIDINE 0.1 N.D.
beta-PHENYLETHYLAMINE HCl 0.1 N.D.




























HEPOXILIN A3 0.001 N.D.





5(S),12(R)-DIHETE all trans 0.001 N.D.
8(R),15(S)-DIHETE all trans 0.001 N.D.
5(S),12(S)-DIHETE all trans  0.001 N.D.
8(S),15(S)-DIHETE all trans 0.001 N.D.
5,6-EPOXYEICOSATRIENOIC ACID 0.001 N.D.
8,9-EPOXYEICOSATRIENOIC ACID 0.001 N.D.
11,12-EPOXYEICOSATRIENOIC ACID 0.001 N.D.
14,15-EPOXYEICOSATRIENOIC ACID 0.001 N.D.
5-KETOEICOSATETRAENOIC ACID 0.001 N.D.
15-KETOEICOSATETRAENOIC ACID 0.001 N.D.
13-KETOOCTADECADIENOIC ACID 0.001 N.D.
LEUKOTRIENE B3 0.001 N.D.
LEUKOTRIENE B4  0.001 N.D.
20-HYDROXY-LEUKOTRIENE B4 0.001 N.D.
20-CARBOXY-LEUKOTRIENE B4 0.001 N.D.
LEUKOTRIENE C4 0.001 N.D.
LEUKOTRIENE D4 0.001 N.D.
LEUKOTRIENE E4 0.001 N.D.
N-ACETYL-LEUKOTRIENE E4 0.001 N.D.
LIPOXIN A4 0.001 N.D.
EPOXY-OLEIC ACID 0.01 N.D.
PROSTAGLANDIN A1 0.01 N.D.
PROSTAGLANDIN A2 0.01 N.D.
PROSTAGLANDIN B1 0.01 N.D.
PROSTAGLANDIN B2 0.01 N.D.
PROSTAGLANDIN D2 0.01 N.D.
PROSTAGLANDIN E1 0.01 N.D.
PROSTAGLANDIN E2 0.01 N.D.
PROSTAGLANDIN F2a 0.01 N.D.
PROSTAGLANDIN F1a 0.01 N.D.
PROSTAGLANDIN I2 Na 0.01 N.D.
15-KETO-PROSTAGLANDIN E2 0.01 N.D.
15-KETO-PROSTAGLANDIN F2a 0.01 N.D.
13,14-DIHYDRO-15-KETO-PGF2a 0.01 N.D.
6-KETO-PROSTAGLANDIN F1a 0.01 N.D.
16,16-DIMETHYL-PROSTAGLANDIN E2 0.01 N.D.
U-46619 0.01 N.D.
9b,11a PROSTAGLANDIN F2  0.01 N.D.
9a,11b PROSTAGLANDIN F2 0.01 N.D.
PROSTAGLANDIN J2 0.01 N.D.
2,3-DINOR-6-KETO-PGF1a 0.001 N.D.
CARBACYCLIN 0.01 N.D.
(±)13-AZAPROSTANOIC ACID 0.01 N.D.
19(R)-HYDROXY-PROSTAGLANDIN E2 0.01 N.D.
19(R)-HYDROXY-PROSTAGLANDIN F2a 0.001 N.D.
17-PHENYL-TRINOR-PGE2 0.01 N.D.
D12-PROSTAGLANDIN J2 0.01 N.D.
13,14-DIHYDRO-PGE1 0.01 N.D.
8-EPI-PROSTAGLANDIN F2a 0.01 N.D.
15d-PGJ2 0.01 N.D.
MISOPROSTOL, FREE ACID 0.01 N.D.
THROMBOXANE B2 0.01 N.D.
11-DEHYDRO-THROMBOXANE B2 0.01 N.D.
ANANDAMIDE (20:4, n-6) 0.01 N.D.
PALMITYLETHANOLAMIDE 0.01 N.D.
ANANDAMIDE (18:2,n-6) 0.01 N.D.
ANANDAMIDE (20:3,n-6) 0.01 N.D.
ANANDAMIDE (22:4,n-6) 0.01 N.D.









S-FARNESYL-L-CYSTEINE ME 0.01 N.D.
AGGC 0.01 N.D.
AGC 0.01 N.D.








LEUKOTOXIN A (9,10-EODE) 0.001 N.D.
LEUKOTOXIN B (12,13-EODE) 0.001 N.D.
12(S)-HHT 0.001 N.D.
25-HYDROXYVITAMIN D3 0.01 N.D.
1,25-DIHYDROXYVITAMIN D3 0.01 N.D.
24,25-DIHYDROXYVITAMIN D3 0.01 N.D.
RETINOIC ACID, ALL TRANS 0.01 N.D.
9-CIS RETINOIC ACID 0.01 N.D.








5,8,11-EICOSATRIYNOIC ACID 0.01 N.D.
5,8,11,14-EICOSATETRAYNOIC ACID 0.01 N.D.
1,2-DIDECANOYL-GLYCEROL (10:0) 0.01 N.D.
1,2-DIOCTANOYL-SN-GLYCEROL 0.01 N.D.
1,2-DIOLEOYL-GLYCEROL (18:1) 0.01 N.D.
1-OLEOYL-2-ACETYL-GLYCEROL 0.01 N.D.
1-STEAROYL-2-ARACHIDONOYL-GLYCEROL 0.01 N.D.




2,3-DINOR-THROMBOXANE B2 0.001 N.D.






CLOPROSTENOL Na 0.01 N.D.
EICOSAPENTAENOIC ACID (20:5 n-3) 0.01 N.D.
DOCOSAHEXAENOIC ACID (22:6 n-3) 0.01 N.D.
ARACHIDONIC ACID (20:4 n-6) 0.01 N.D.
MEAD ACID (20:3 n-9) 0.01 N.D.
LINOLENIC ACID (18:3 n-3) 0.01 N.D.
GAMMA-LINOLENIC ACID (18:3 n-6) 0.01 N.D.
EICOSA-5,8-DIENOIC ACID (20:2 n-12) 0.01 N.D.
EICOSADIENOIC ACID (20:2 n-6) 0.01 N.D.
7,7-DIMETHYLEICOSADIENOIC ACID 0.01 N.D.
EICOSATRIENOIC ACID (20:3 n-3) 0.01 N.D.
DIHOMO-GAMMA-LINOLENIC ACID 0.01 N.D.
DOCOSATRIENOIC ACID (22:3 n-3) 0.01 N.D.
ADRENIC ACID (22:4 n-6) 0.01 N.D.
DOCOSAPENTAENOIC ACID  0.01 N.D.
LINOLEIC ACID 0.01 N.D.
17-OCTADECYNOIC ACID 0.01 N.D.
2-HYDROXYMYRISTIC ACID 0.01 N.D.
2-FLUOROPALMITIC ACID 0.01 N.D.
4-OXATETRADECANOIC ACID 0.01 N.D.
12-METHOXYDODECANOIC ACID 0.01 N.D.
SPHINGOSINE  0.01 N.D.
C2 CERAMIDE 0.01 N.D.
C2 DIHYDROCERAMIDE 0.01 N.D.
N,N-DIMETHYLSPHINGOSINE 0.01 N.D.
C8 CERAMIDE 0.01 N.D.
C8 DIHYDROCERAMIDE 0.01 N.D.




SPHINGOSYLPHOSPHORYL CHOLINE 0.01 N.D.
DIHYDROSPHINGOSINE-1-PHOSPHATE 0.01 N.D.




MAPP, D-erythro 0.01 N.D.
MAPP, L-erythro 0.01 N.D.
PAF C16 0.01 N.D.
LYSO-PAF C16 0.01 N.D.
PAF C18 0.01 N.D.
LYSO-PAF C18 0.01 N.D.
PAF C18:1 0.01 N.D.





1-HEXADECYL-2-METHYLGLYCERO-3 PC 0.01 N.D.
1-OCTADECYL-2-METHYLGLYCERO-3 PC 0.01 N.D.
C-PAF 0.01 N.D.
1-ACYL-PAF 0.01 N.D.
LYSOPHOSPHATIDIC ACID 0.01 N.D.
L-NASPA 0.01 N.D.
PHOSPHATIDIC ACID, DIPALMITOYL 0.01 N.D.
AM-251 0.01 N.D.
2-ARACHIDONOYLGLYCEROL 0.01 N.D.
6-FORMYLINDOLO [3,2-B] CARBAZOLE 0.01 N.D.
DIINDOLYLMETHANE 0.01 N.D.
N-LINOLEOYLGLYCINE 0.01 N.D.
PALMITOYL DOPAMINE 0.01 N.D.
OLEOYL DOPAMINE 0.01 N.D.











Palmitoyl ethanolamide 0.01 N.D.
Oleoyl ethanolamide 0.01 N.D.
Linoleoyl ethanolamide 0.01 N.D.
gamma-Linolenoyl ethanolamide 0.01 N.D.
Eicosa-11Z,14Z-dienoyl ethanolamide 0.01 N.D.
Dihomo-gamma-linolenoyl ethanolamide 0.01 N.D.
Arachidonoyl ethanolamide 0.01 N.D.
Eicosapentaenoyl ethanolamide 0.01 N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl ethanolamide 0.01 N.D.
Docosahexaenoyl ethanolamide 0.01 N.D.
Palmitoyl glycine 0.01 N.D.
Oleoyl glycine 0.01 N.D.
Linoleoyl glycine 0.01 N.D.
gamma-Linolenoyl glycine 0.01 N.D.
Eicosa-11Z,14Z-dienoyl glycine 0.01 N.D.
Dihomo-gamma-linolenoyl glycine 0.01 N.D.
Arachidonoyl glycine 0.01 N.D.
Eicosapentaenoyl glycine 0.01 N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl glycine 0.01 N.D.
Docosahexaenoyl glycine 0.01 N.D.
Palmitoyl alanine 0.01 N.D.
Oleoyl alanine 0.01 N.D.
Linoleoyl alanine 0.01 N.D.
gamma-Linolenoyl alanine 0.01 N.D.
Eicosa-11Z,14Z-dienoyl alanine 0.01 N.D.
Dihomo-gamma-linolenoyl alanine 0.01 N.D.
Arachidonoyl alanine 0.01 N.D.
Eicosapentaenoyl alanine 0.01 N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl alanine 0.01 N.D.
Docosahexaenoyl alanine 0.01 N.D.
Palmitoyl GABA 0.01 N.D.
Oleoyl GABA 0.01 N.D.
Linoleoyl GABA 0.01 N.D.
gamma-Linolenoyl GABA 0.01 N.D.
Eicosa-11Z,14Z-dienoyl GABA 0.01 N.D.
Dihomo-gamma-linolenoyl GABA 0.01 N.D.
Arachidonoyl GABA 0.01 N.D.
Eicosapentaenoyl GABA 0.01 N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl GABA 0.01 N.D.
Docosahexaenoyl GABA 0.01 N.D.
Palmitoyl dopamine 0.01 N.D.
Oleoyl dopamine 0.01 N.D.
Linoleoyl dopamine 0.01 N.D.
gamma-Linolenoyl dopamine 0.01 N.D.
Eicosa-11Z,14Z-dienoyl dopamine 0.01 N.D.
Dihomo-gamma-linolenoyl dopamine 0.01 N.D.
Arachidonoyl dopamine 0.01 N.D.
Eicosapentaenoyl dopamine 0.01 N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl dopamine 0.01 N.D.
Docosahexaenoyl dopamine 0.01 N.D.
L-Tartaric Acid bishydrazide 0.01 N.D.
Oxalacetic Acid, Free of Chlorid 0.01 N.D.
Meso-Tartaric Acid, Monohydrate 0.01 N.D.
Sodium L-Malate 0.01 N.D.
cis-Aconitic Acid 0.01 N.D.
Oxalic Acid, Free Acid 0.01 N.D.
Glyoxylic Acid, Monohydrate 0.01 N.D.
Succinic Acid 0.01 N.D.
Oxalacetic Acid, Cell Culture Reagent, 0.01 N.D.
Glycolic Acid, 0.01 N.D.
Glycolaldehyde 0.01 N.D.
Acetoacetic Acid Lithium Salt 0.01 N.D.
Propiolic Acid, 0.01 N.D.
3-Hydroxypropionic Acid 0.01 N.D.
3-Aminopropionic Acid 0.01 N.D.
1-Aminocyclobutane-Carboxylic Acid 0.01 N.D.
Succinic Acid 0.01 N.D.
Propionic Acid, Free Acid 0.01 N.D.
4-aminobutanoic acid 0.01 N.D.
Diacetyl (Biacetyl; 2,3-Butanedione; DimethyIglyoxal; Dimethyl Diketone) 0.01 N.D.
(2R,3R)-(-)-2,3-Butanediol 0.01 N.D.
(2S,3S)-(+)-2,3-Butanediol 0.01 N.D.
Fumaric Acid 0.01 N.D.
Maleic Acid Hydrazide, 0.01 N.D.
D-Malic Acid 0.01 N.D.
Butyraldehyde (Butanal) 0.01 N.D.
4-Hydroxybutyric Acid Hydrazide 0.01 N.D.
(R)-(-)-3-Hydroxybutyric Acid, Sodium Salt 0.01 N.D.
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 0.01 N.D.
SODIUN THIOSULFATE 0.01 N.D.
APS 0.01 N.D.
O-Acetyl-L-homoserine 0.01 N.D.
Palmityl Alcohol 0.01 N.D.
Palmitaldehyde/sodium Bisulfite Addition Compound 0.01 N.D.
Vitamin K 1 0.01 N.D.
Ergosterol Acetate, Vitamin E Determination 0.01 N.D.
Catechol, alpha-Carotene, 9mg/mL 0.01 N.D.
Phytosterol 0.01 N.D.
4-Cholesten-3-one 0.01 N.D.
Nor-Deoxycholic Acid 0.01 N.D.
Methyl Chenodeoxycholate 0.01 N.D.
Lithocholic Acid, 0.01 N.D.
Progesterone 0.01 N.D.
Hydrocortisone-21-Acetate, 0.01 N.D.


























3β-(2-Diethylamino-Ethoxy)Androstenone, Hydrochloride 0.01 N.D.
Testosterone, 99.0% (GC Assay) 0.01 N.D.
d\-Androsten-17b-Ol-3-one - Carc., 0.01 N.D.
Primoteston - Carc., 0.01 N.D.
β-Estradiol 3-Sulfate 17-Glucuronide, Dipotassium Salt 0.01 N.D.
Etiocholan-3b-Ol-17-one 0.01 N.D.
17b-(1-Methyl-3-Carboxypropyl)etiocholane-3a 12a-Diol Sodium Salt 0.01 N.D.
Estrone (1,3,5-Estratriene-3-ol-17-one) 0.01 N.D.
Estriol 0.01 N.D.
17α-Ethinyl Estradiol 0.01 N.D.
β-Estradiol-17-Cypionate 0.01 N.D.
1 4-Androstadien-17b-Ol-3-one 0.01 N.D.
3b-Hydroxy-5-Androsten-17-one 0.01 N.D.











D-Ribose-5-Phosphate, Disodium Salt 0.01 N.D.
Glycinamide, Hydrochloride 0.01 N.D.
5(4)-Aminoimidazole-4(5)-Carboxamide, Hydrochloride 0.01 N.D.
5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside [Aicar] 0.01 N.D.
2',3'-o-Isopropylidene-Inosine 0.01 N.D.
Inosine, 99% 0.01 N.D.
Inosine-5'-Monophosphate, Free Acid 0.01 N.D.
3-Acetylpyridine-DeAmino-Nad, Sodium Salt 0.01 N.D.
Hypoxanthine, Disodium Salt, 0.01 N.D.
Hypoxanthine-9-β-D-Arabinofuranoside 0.01 N.D.
Xanthine, Sodium Salt 0.01 N.D.
Xanthosine, Dihydrate 0.01 N.D.
Xanthosine-5'-Monophosphate, Disodium Salt, Monohydrate 0.01 N.D.
Xanthone 0.01 N.D.
8-(3-Chlorostyryl)Caffeine 0.01 N.D.
Allantoic Acid 0.01 N.D.
Allantoin 0.01 N.D.
N-Carbamyl-DL-Aspartic Acid 0.01 N.D.
Dihydro-DL-Orotic Acid 0.01 N.D.
beta-Pseudouridine 0.01 N.D.
Pseudouridine, from Wheat Bran 0.01 N.D.
DihydrOuracil 0.01 N.D.
Carbamoyl-beta-Ala-OH (3-Ureidopropionic acid) 0.01 N.D.
Albizziin [L-(-)-2-Amino-3-Ureidopropionic Acid] 0.01 N.D.
Barbituric Acid 0.01 N.D.
5-Ethyl-5-(p-Hydroxy-Phenyl)Barbituric Acid 0.01 N.D.
Cytosine-β-D-Arabinofuranoside, Hydrochloride 0.01 N.D.
Cytosine, Ultra Pure 0.01 N.D.
Cytidine, Free Base 0.01 N.D.
Cytidine-5'-Diphosphoglucose, Disodium Salt 0.01 N.D.
Cytidine-3'-Monophosphate, Free Acid, 98+% 0.01 N.D.
Cytidine-2',3'-Cyclic-Monophosphate, Barium Salt 0.01 N.D.
Cytidine-5'-Triphosphate, Disodium Salt, Dihydrate 0.01 N.D.
Thymidine-5'-Monophosphate, Disodium Salt 0.01 N.D.
Thymidine-5'-Diphosphate, Trisodium Salt 0.01 N.D.




1-Hydroxypyridine-2-Thione, Zinc Salt 0.01 N.D.
Dihydrothymine 0.01 N.D.
5, 6-Dihydrothymidine 0.01 N.D.
Ethyl 3-Amino-3-Ureidobutyrate 0.01 N.D.
2-Aminoisobutane 0.01 N.D.
2-Oxoglutaric Acid 0.01 N.D.
Dimethyl 3-Oxoglutarate 0.01 N.D.
gDGG (g-D-Glutamylglycine), NMDA Antagonist 0.01 N.D.
2-aminobutanoic acid 0.01 N.D.
4-aminobutanoic acid 0.01 N.D.
DL-Homocystine 0.01 N.D.
S-Acetyl Mercapto-Succinic Anhydride 0.01 N.D.
Meso-2,3-Dimercapto-Succinic Acid 0.01 N.D.
Acetyl-DL-Carnitine, Hydrochloride 0.01 N.D.
Phosphoenolpyruvic Acid, Monopotassium Salt 0.01 N.D.
Calcium 3-Phospho-D-Glycerate 0.01 N.D.
Sarcosine Anhydride 0.01 N.D.
DL-Allothreonine 0.01 N.D.
α-Ketoisovaleric Acid, Sodium Salt 0.01 N.D.
5-Aminovaleric Acid 0.01 N.D.
DL-Cystathionine 0.01 N.D.
Oleyl Amido Betaine 0.01 N.D.
Betaine Hydrate 0.01 N.D.
Taurocholic Acid 0.01 N.D.
S-2-Aminoethyl-L-Cysteine, Hydrochloride 0.01 N.D.
L-Cysteinesulfinic Acid, Monohydrate 0.01 N.D.
2-Aminoethylphosphonic Acid 0.01 N.D.
Diethyl Methylthiomethylphosphonate 0.01 N.D.







D-Glucuronic Acid 0.01 N.D.
2-Keto-D-Gluconic Acid, Hemicalcium Salt 0.01 N.D.
D-(P)-Glucosaminic Acid 0.01 N.D.
D-Glucono-δ-Lactone 0.01 N.D.
Glucuronamide 0.01 N.D.
Resorufin β-D-Glucuronide, Sodium Salt 0.01 N.D.
Chondroitin Sulfate A, from Shark Notocord, Sodium Salt 0.01 N.D.
Chondroitin Sulfate D, from Shark Cartilage, Sodium Salt 0.01 N.D.
Chondroitin Sulfate C, from Shark Cartilage, Sodium Salt 0.01 N.D.
saturated fatty acids
C6 0.1 N.D.
C7 0.1 N.D.
C8 0.1 N.D.
C9 0.1 N.D.
C10 0.1 N.D.
C12 0.1 N.D.
C14 0.1 N.D.
C16 0.1 N.D.
C17 0.1 N.D.
C18 0.1 N.D.
C20 0.1 N.D.
C21 0.1 N.D.
C22 0.1 N.D.
C23 0.1 N.D.
N.D., not detectable
